Literature DB >> 27454834

Propofol in the treatment of refractory migraine headaches.

Ashish Dhir1.   

Abstract

INTRODUCTION: Refractory/intractable migraine headaches are associated with chronic pain that does not respond to standard care of treatment. Propofol(2,6-diisopropylphenol) in sub-anesthetic doses has been reported to be beneficial in such patients. The present article describes the complete drug profile of propofol in the management of these super-refractory migraine headaches. AREAS COVERED: The article covers different preclinical and clinical studies available in the literature. Expert commentary: Propofol is useful as an off-label drug molecule in an emergency situation of refractory migraines where it has been found to reduce the pain intensity. The molecule with a narrow therapeutic index and high abuse potential is prescribed only when conventional drugs fail to deliver any relief. There are not adequate double-blind crossover studies that substantiate the effectiveness of propofol in the treatment of migraine headaches. Furthermore, long-term outcomes for the use of propofol in migraine headaches requires an extensive investigation.

Entities:  

Keywords:  Propofol; clinical studies; cortical spreading depression; refractory migraine; safety analysis

Mesh:

Substances:

Year:  2016        PMID: 27454834     DOI: 10.1080/14737175.2016.1216795

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  2 in total

1.  Migraine Headaches after Major Surgery with General or Neuraxial Anesthesia: A Nationwide Propensity-Score Matched Study.

Authors:  Chung-Yi Liao; Chun-Cheng Li; Hsin-Yi Liu; Jui-Tai Chen; Yih-Giun Cherng; Tzeng-Ji Chen; Ying-Xiu Dai; Hsiang-Ling Wu; Wan-Chi Liu; Ying-Hsuan Tai
Journal:  Int J Environ Res Public Health       Date:  2021-12-30       Impact factor: 3.390

Review 2.  A Systems Neuroscience Approach to Migraine.

Authors:  K C Brennan; Daniela Pietrobon
Journal:  Neuron       Date:  2018-03-07       Impact factor: 17.173

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.